Pharmacokinetic Drug Interactions with ACE Inhibitors

@article{Shionoiri1993PharmacokineticDI,
  title={Pharmacokinetic Drug Interactions with ACE Inhibitors},
  author={Hiroshi Shionoiri},
  journal={Clinical Pharmacokinetics},
  year={1993},
  volume={25},
  pages={20-58}
}
SummaryAngiotensin converting enzyme (ACE) inhibitors which have active moieties excreted mainly in urine require adjustment of either the dose or the interval between doses in patients with moderate to severe renal dysfunction or severe congestive heart failure. Those agents such as temocapril (CS 622) and fosinopril, excreted both in urine and bile, may not require such adjustment. Renal clearance of ACE inhibitors may be reduced and some accumulation may occur in elderly patients with mild… Expand
ACE Inhibitors
TLDR
There is some evidence, albeit scant, linking ACE inhibitors with the induction of lithium toxicity in patients maintained on lithium, and with the occurrence of severe hypersensitivity reactions in patients undergoing haemodialysis, venom immunisation or concomitant allopurinol therapy. Expand
Optimal Dosage of ACE Inhibitors in Older Patients
TLDR
It is safer to use lower initial dosages of ACE inhibitors in elderly hypertensive patients because hypotensive reactions are not always predictable and it is necessary to interrupt diuretic treatment for a few days to prevent severe hypotension. Expand
Etiology and Treatment of Angiotensin Converting Enzyme Inhibitor-Induced Cough
ABSTRACT Angiotensin-converting enzyme inhibitors (ACEls) are widely used in the treatment of hypertension and congestive heart failure (CHF). They have also been shown to slow the progression ofExpand
Fosinopril. Clinical pharmacokinetics and clinical potential.
TLDR
The available evidence suggests that the pharmacokinetic variables of fosinoprilat in patients receiving haemodialysis were similar to those in patients with moderate to severe renal dysfunction, and thus dosage modifications or supplemental dose administration following dialysis may be unnecessary. Expand
Renin–Angiotensin Blockade: Therapeutic Agents
Publisher Summary This chapter discusses the therapeutic use of rennin–angiotensin blockade. Several drug classes are known to interfere with renin–angiotensin system (RAS) activity includingExpand
ACE Inhibitors and the Kidney
TLDR
Patients at the greatest risk for renal adverse effects (those with heart failure, diabetes mellitus and/or chronic renal failure) also can expect the greatest benefit from ACE inhibitors, but dosages should be carefully titrated, with monitoring of renal function and serum potassium levels. Expand
Drug interactions with angiotensin receptor blockers
TLDR
Compared to other classes of antihypertensive agents, the ARBs appear to have a low potential for drug interactions; however, interactions with this class occur and variations within the class have been detected, mainly due to different affinities for cytochrome P450 isoenzymes. Expand
Drug Interactions with Angiotensin Receptor Blockers: A Comparison with Other Antihypertensives
TLDR
Patients should be made aware of possible interactions, especially involving the concurrent use of over-the-counter products, and it may be prudent for all patients receiving antihypertensive treatment to be monitored for possible drug interactions at their regular check-ups. Expand
Angiotensin-converting enzyme inhibitors may cause renal dysfunction in patients on long-term lithium treatment.
  • K. Lehmann, E. Ritz
  • Medicine
  • American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 1995
TLDR
It is proposed that renal function should be closely monitored when patients on lithium treatment are given angiotensin-converting enzyme inhibitors and that doses of both drugs should be chosen with caution to avoid serious drug interaction. Expand
Drug Interactions with Irbesartan
TLDR
Irbesartan has demonstrated minimal potential for drug or food interactions in trials conducted to date, and Fluconazole did increase the steady-state peak plasma concentration and area under the concentration-time curve, but these increases are not likely to be clinically significant. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 173 REFERENCES
Pharmacokinetic Optimisation of Angiotensin Converting Enzyme (ACE) Inhibitor Therapy
TLDR
Among the pharmacokinetic characteristics of ACE inhibitors the route of excretion and to a lesser degree the half-life appear to be the most clinically relevant and there is no evidence that being a prodrug offers a significant clinical advantage. Expand
Clinical Pharmacokinetics of the Angiotensin Converting Enzyme Inhibitors
TLDR
The available data suggest that enalapril's pharmacokinetic properties in patients with congestive heart failure resemble those in healthy subjects, however, additional data are necessary to confirm this. Expand
Nephrotoxicity Associated With Concomitant ACE Inhibitor and NSAID Therapy
TLDR
Significant nephrotoxicity during the concomitant use of ACE inhibitors and NSAIDs is not uncommon, and attention should be drawn to this potentially important interaction. Expand
Combination of converting enzyme inhibitor with diuretic for the treatment of hypertension.
TLDR
The combination of converting enzyme inhibitor and diuretic provides an ideal choice in terms of efficacy, compliance, side effects, and cost. Expand
The current status of angiotensin converting enzyme inhibitors in the management of patients with chronic heart failure.
TLDR
The unique characteristics of the ACE inhibitors support their use as first-line agents in patients with chronic heart failure, especially when efforts are made to block the formation of angiotensin (Ang) II continuously. Expand
Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.
TLDR
Enalapril 10 to 40 mg/day administered either once or twice daily is effective in lowering blood pressure in all grades of essential and renovascular hypertension, and shows similar efficacy to usual therapeutic dosages of hydrochlorothiazide, beta-blockers and captopril. Expand
Metabolic effects of ACE inhibitors.
  • C. Berne
  • Medicine
  • Journal of internal medicine. Supplement
  • 1991
TLDR
It remains to be established whether this effect of captopril can be extrapolated to other ACE inhibitors, and the extent to which effects on insulin sensitivity will influence the long-term consequences for future risk of diabetes mellitus and coronary heart disease in patients with essential hypertension. Expand
Antihypertensive effects and pharmacokinetics of single and consecutive doses of cilazapril in hypertensive patients with normal and impaired renal function.
TLDR
It is suggested that cilazapril has a long-lasting action and that it is a useful antihypertensive agent for controlling blood pressure in patients with either NRF or IRF. Expand
Pharmacokinetics and Antihypertensive Effects of Lisinopril in Hypertensive Patients with Normal and Impaired Renal Function
TLDR
It is suggested that lisinopril has a long-lasting action and that it is a useful antihypertensive agent for controlling BP in patients with either NRF or mild IRF, and when administered for an extended period, more careful consideration should be given to the dose. Expand
Antihypertensive effects of nitrendipine and cilazapril alone, and in combination in hypertensive patients with chronic renal failure.
TLDR
The acute and chronic antihypertensive effects of the calcium antagonist nitrendipine and the new ACE inhibitor cilazapril, given alone, and in combination, are investigated in a double-blind, randomized, placebo controlled study of 11 hypertensive patients with chronic renal failure. Expand
...
1
2
3
4
5
...